Conversation with Isabell Remus

What does it take to get a life-changing medicine from regulatory approval to the patient who needs it? Isabell Remus, Global Head of Biosimilars at Sandoz, reveals why being approved and affordable isn't enough – and how the biosimilar industry learned that trust and education must come before market access. With $320 billion in biologic medicines losing patent exclusivity over the next decade, she explores the strategic complexities of launching at the exact moment a patent expires, the role of diversified manufacturing in strengthening supply chain resilience, and why expanding access to essential medications requires both purpose and commercial viability. An eye-opening conversation on making affordable healthcare a reality for millions of patients worldwide.